Mounjaro vs Zepbound: Same Molecule, Different Price Paths
This is the comparison where the usual question ("which drug is stronger?") has a boring answer: they are the same drug. Both are tirzepatide, Eli Lilly's dual GLP-1/GIP agonist, on the same 2.5 to 15 mg weekly titration. What actually differs is the FDA label - Mounjaro for type 2 diabetes, Zepbound for chronic weight management - and that label decides your insurance path, your savings card, and whether the cheapest cash option ($299/mo LillyDirect vials) is even available to you.
Read this first: one molecule, two labels
- If you have type 2 diabetes: Mounjaro is on-label, usually covered, and its savings card can bring a covered commercial copay to about $25/fill. If you are weighing it against semaglutide, the comparison you want is Ozempic vs Mounjaro.
- If your goal is weight loss without a T2D diagnosis: Zepbound is the on-label choice, and the only one of the two with a manufacturer self-pay program. The other comparison worth running is Wegovy vs Zepbound.
Weight loss comparison (220 lbs starting weight)
% of body weight lost over 18 months, modeled from phase 3 trial data
The curves differ because the underlying trials enrolled different populations (SURMOUNT-1: obesity without diabetes; SURPASS: type 2 diabetes), not because the molecule differs. Expect your own result to track your diagnosis group, whichever label is on the pen.
The 12-month cash-pay math
Since the medicine is identical, the cash-pay question reduces to: what does a year of tirzepatide cost on each label's cheapest branded route?
| Label | Cheapest branded route | Monthly | 12 months |
|---|---|---|---|
| Mounjaro | Branded telehealth | $499 | $5,988 |
| Zepbound | LillyDirect vials (starter dose) | $299 | $3,588 |
Same molecule, roughly $2,400/year apart at the starter dose - entirely a function of which label unlocks the LillyDirect program. Zepbound's LillyDirect price is dose-tiered ($299 for 2.5 mg, $399 for 5 mg, $449 for 7.5 mg and up, within the 45-day refill window) and ships as vial-and-syringe rather than a pen. Pricing as of July 2026. See sources for trial citations.
Monthly cost by payment channel
| Channel | Mounjaro | Zepbound |
|---|---|---|
| Insurance copay (typical) | $88 | $88 |
| Manufacturer self-pay (LillyDirect) | - | $299 |
| Branded telehealth | $499 | $499 |
| Cash retail (full WAC) | $1,069 | $1,059 |
Honesty notes: Mounjaro's copay assumes a type 2 diabetes diagnosis (it is not covered for weight loss alone); Zepbound's assumes a plan that covers weight-loss drugs at all, usually behind a prior authorization. Mounjaro shows a dash for manufacturer self-pay because the LillyDirect discount program is Zepbound-only. Pricing as of July 2026.
The Medicare wrinkle (2026)
Medicare Part D covers Mounjaro for type 2 diabetes the ordinary way - but not for weight loss, which is excluded by statute. Starting July 1, 2026, the Medicare GLP-1 Bridge program adds Zepbound KwikPen at a flat $50/month Part D copay under BMI-based eligibility rules. Two traps worth knowing: the Bridge covers the KwikPen only (not LillyDirect vials), and Mounjaro is not part of the Bridge at all - diabetes-indicated drugs are ineligible. Full Medicare GLP-1 Bridge guide →
Which one fits your situation?
Mounjaro if: you have type 2 diabetes. It is on-label, most plans cover it, and the Mounjaro Savings Card can bring a covered commercial copay to about $25/fill. There is no reason to fight for off-label Zepbound coverage when the same molecule is covered under its diabetes label.
Zepbound if: weight management is the goal and you do not have a T2D diagnosis - it is the on-label choice - or you are paying cash at any point, because LillyDirect vials ($299 to $449/month by dose) are the cheapest branded tirzepatide in the US and simply do not exist on the Mounjaro side.
Either way: do not pay $1,069/mo list price for Mounjaro as a cash-pay weight-loss patient. Ask your prescriber whether writing for Zepbound instead unlocks the LillyDirect path - same molecule, same titration, different invoice.
Educational content only, not a treatment recommendation. Any switch or new prescription should go through a licensed prescriber.
Where to actually get tirzepatide (and the alternatives)
Manufacturer direct prices (LillyDirect, NovoCare) are usually cheapest. Updated May 2026.
| Drug | Insurance | Mfr direct | Telehealth (brand) | Telehealth (compd) | Cash retail | Get it |
|---|---|---|---|---|---|---|
| Wegovy 14.9% weight loss | $63 | $349 | $329 | $249 cheapest | $1,349 | Get →ad |
| Ozempic 11.6% weight loss | $63 | - | $399 | $199 cheapest | $1,028 | Get →ad |
| Wegovy (oral 25mg) 13.6% weight loss | $63 | $149 cheapest | $449 | - | $1,349 | Get →ad |
| Zepbound 22.5% weight loss | $88 | $299 cheapest | $499 | $299 cheapest | $1,059 | Get →ad |
| Mounjaro 20.9% weight loss | $88 | - | $499 | $299 cheapest | $1,069 | Get →ad |
| Saxenda 8.4% weight loss | $63 | - | $399 cheapest | - | $1,349 | Get →ad |
| Foundayo (orforglipron) 14.7% weight loss | $63 | $149 cheapest | - | - | $1,099 | Get →ad |
Frequently asked questions
Are Mounjaro and Zepbound actually the same drug?
Chemically, yes: both are tirzepatide, Eli Lilly's dual GLP-1/GIP receptor agonist, at the same dose ladder (2.5 mg up to 15 mg, weekly injection). What differs is the FDA label. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. That single word on the label controls everything downstream: which diagnosis your insurer requires, which savings card you can use, and whether the LillyDirect self-pay program is open to you (it is Zepbound-only).
Why do the trial numbers differ if the molecule is identical?
Zepbound's 22.5% comes from SURMOUNT-1, which enrolled patients with obesity and no diabetes. Mounjaro's 20.9% figure traces to the SURPASS program in type 2 diabetes, and people with T2D consistently lose somewhat less weight on any GLP-1 than people without it. The gap is a population effect, not a potency difference - the same person taking either pen at the same dose gets the same drug.
Which is cheaper without insurance?
Zepbound, decisively, because of one program: LillyDirect self-pay vials start around $299/month for the 2.5 mg starter dose ($399 for 5 mg, $449 for 7.5 mg and up, within the 45-day refill window). Mounjaro has no equivalent - Eli Lilly does not sell Mounjaro through the LillyDirect discount program, so branded Mounjaro without insurance means telehealth at roughly $499/month or full list price at $1,069/month. A cash-pay patient who wants tirzepatide should almost always be asking their prescriber about Zepbound, not Mounjaro.
Can my prescriber just swap one for the other?
Clinically it is the same molecule and the same titration, so a swap is medically straightforward - but it is still a new prescription for a differently-labeled drug, and insurance treats it that way. Moving from Mounjaro to Zepbound usually means a new prior authorization against your plan's weight-management criteria; moving from Zepbound to Mounjaro requires a type 2 diabetes diagnosis for coverage. Some plans also apply step therapy, for example requiring Mounjaro first before approving Zepbound for a patient with T2D. Talk to your prescriber about which label fits your diagnosis and plan.
Does Medicare cover Mounjaro or Zepbound?
Medicare Part D covers Mounjaro for type 2 diabetes - that is an ordinary formulary matter, since it is a diabetes-indicated drug. Medicare does not cover drugs prescribed solely for weight loss, which historically shut Zepbound out. The change in 2026: the Medicare GLP-1 Bridge program adds Zepbound KwikPen at a flat $50/month copay on Part D starting July 1, 2026, with BMI-based eligibility rules. Two traps: the Bridge covers the Zepbound KwikPen only (not LillyDirect vials), and it does not include Mounjaro at all (diabetes-indicated drugs are ineligible - they already have the normal Part D path).
Do the savings cards transfer between them?
No. Each card is tied to its own drug. The Mounjaro Savings Card drops a commercial-insurance copay to as little as $25 per fill when your plan covers Mounjaro (Lilly covers up to $150/month, card through 12/31/2026, up to 13 fills per 12-month period). The Zepbound Savings Card has its own two paths: about $25/fill if your commercial plan covers Zepbound, or the non-covered KwikPen path at $299 to $449/month by dose if it does not. Both cards exclude government insurance (Medicare, Medicaid, TRICARE, VA) under the federal anti-kickback statute.
Are the side effects different?
No meaningful difference is expected - it is the same molecule at the same doses, so the profile is the same: nausea, diarrhea, constipation, and vomiting, concentrated during dose escalation and usually improving at a stable dose. Individual experiences vary, but switching between Mounjaro and Zepbound to escape side effects does not have a pharmacological basis the way switching molecules (say, semaglutide to tirzepatide) does.
I have both type 2 diabetes and obesity - which one?
That is a prescriber-and-insurance question more than a drug question, since the medicine is identical. In practice, insurance usually decides: with a T2D diagnosis, Mounjaro is on-label and most plans cover it, so it is typically the path of least resistance (and the Mounjaro Savings Card can bring a covered copay to $25/fill). Zepbound becomes relevant if your plan's diabetes formulary excludes Mounjaro but its weight-management benefit covers Zepbound, or if you lose coverage entirely and need the LillyDirect cash price.
Related guides
Stay ahead of every GLP-1 development
We'll email you when something actually matters: new FDA approvals (Foundayo, CagriSema, retatrutide), pricing drops at LillyDirect/NovoCare, telehealth deals, clinical trial results, FDA recalls, and insurance policy changes. ~1-2 emails/month. No filler.